FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 681 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR A call to action: how our Campaigns Ambassadors are shaping the... May 6, 2022 Cancer in My Community: Expanding Genetic Testing in Thailand October 11, 2022 After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family January 4, 2022 High-Fat Diet or Diabetes Drug May Enhance Response to Targeted Cancer... August 8, 2018 Load more HOT NEWS Delivering Palliative Care by Telehealth Meets the Needs of People with... EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or... What to Know About Navigating Cancer Care With a Disability: An...
